IDH1
IDH1 encodes a critical metabolic enzyme that produces alpha-ketoglutarate and NADPH. Mutations in IDH1 are a hallmark of gliomas and leukemias, leading to the production of the "oncometabolite" 2-hydroxyglutarate, which rewires the cell’s entire epigenetic landscape.
Key Takeaways
- •IDH1 is a master metabolic engine that produces fuel (NADPH) and signals (α-KG).
- •Mutations (e.g., R132H) convert the enzyme into a "factory" for a toxic chemical (2-HG).
- •This toxic chemical (2-HG) blocks DNA repair and locks cells in an immature state.
- •IDH1 inhibitors are modern precision drugs used to treat leukemias and brain tumors.
Basic Information
- Gene Symbol
- IDH1
- Full Name
- Isocitrate Dehydrogenase (NADP(+)) 1
- Also Known As
- HEL-S-26IDCDIDHIDPPICD
- Location
- 2q33.3
- Protein Type
- Metabolic Enzyme
- Protein Family
- Isocitrate dehydrogenase family
Related Isoforms
Key SNPs
The defining "R132H" oncogenic mutation. Found in ~80% of grade II/III gliomas and secondary glioblastomas; drives the production of the oncometabolite 2-HG.
A synonymous variant frequently studied as a genetic marker; associated with altered risk and clinical course in certain AML cohorts.
Common marker used in GWAS panels to identify the IDH1 locus and its association with metabolic and neurological traits.
Overview
IDH1 (Isocitrate Dehydrogenase 1) encodes an enzyme that resides in the cytoplasm and peroxisomes. Its primary metabolic function is to catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), while simultaneously producing NADPH. This reaction is a critical source of reducing power for antioxidant defense and fatty acid synthesis, making IDH1 a central pillar of cellular energy and redox balance.
The significance of IDH1 in medicine was transformed by the discovery of its role in oncology. Specific mutations in IDH1—most famously the R132H variant—endow the enzyme with a "neo-morphic" (new) activity. Instead of making α-KG, the mutant enzyme produces massive amounts of 2-hydroxyglutarate (2-HG). This "oncometabolite" acts as a competitive inhibitor of numerous oxygenases, including the TET enzymes that manage DNA methylation, effectively hijacking the cell’s epigenetic control and driving the development of gliomas and acute myeloid leukemia (AML).
Conceptual Model
A simplified mental model for the pathway:
Mutant IDH1 turns a healthy metabolic signal into a destructive epigenetic toxin.
Core Health Impacts
- • Redox Balance: Primary source of cytoplasmic NADPH required for glutathione-mediated antioxidant defense
- • Epigenetic Regulation: Produces alpha-ketoglutarate, the essential cofactor for DNA and histone demethylases
- • Oncogenesis: Neo-morphic mutations drive the formation of gliomas, chondrosarcomas, and AML
- • Lipid Synthesis: Provides the reducing power and carbon skeletons needed for fatty acid and cholesterol production
- • HIF-1α Stability: Regulates the response to hypoxia by providing the cofactor needed to degrade HIF proteins
Protein Domains
Isocitrate Binding Site
The catalytic pocket where isocitrate is captured and converted; the site of the R132 mutation.
NADP+ Binding Fold
A structural motif that coordinates the coenzyme needed to capture electrons during the reaction.
Dimerization Interface
IDH1 functions as a homodimer; mutations can impact the structural stability and cooperation between subunits.
Upstream Regulators
Isocitrate Activator
The primary substrate; high levels provide the building blocks for IDH1-mediated synthesis.
NADP+ Activator
The essential electron acceptor; its availability dictates the speed of the catalytic cycle.
Citrate Activator
Metabolic precursor that can be converted to isocitrate to fuel the IDH1 engine.
HIF-1α Activator
Transcription factor that can upregulate IDH1 expression to support cellular survival under low oxygen.
Oncogenic Mutations Modulator
Structural changes like R132H that fundamentally alter the enzyme's substrate preference.
Downstream Targets
alpha-Ketoglutarate (α-KG) Activates
The healthy product; required for the function of over 60 diverse cellular oxygenases.
NADPH Activates
The universal reducing agent needed for antioxidant defense and lipid synthesis.
2-Hydroxyglutarate (2-HG) Activates
The "oncometabolite" produced by mutant IDH1; it competes with α-KG to block healthy enzymes.
DNA Demethylases (TET) Inhibits
Inhibited by mutant-derived 2-HG, leading to global DNA hypermethylation.
Histone Demethylases (KDM) Inhibits
Inhibited by 2-HG, preventing the normal remodeling of chromatin and locking cells in an immature state.
Role in Aging
IDH1 is at the center of the "metabolic-epigenetic" theory of aging. As we age, the precision of our IDH1-mediated redox control declines, while the accumulation of somatic IDH1 mutations creates local "hotspots" of epigenetic chaos that accelerate tissue decay and tumor development.
Redox Exhaustion
Age-related declines in IDH1-mediated NADPH production reduce the cell's ability to clear the ROS that drive biological aging.
Epigenetic Drift
Declining α-KG levels in late life can impair the TET enzymes, contributing to the global loss of epigenetic precision seen in the elderly.
Clonal Accumulation
Somatic IDH1 mutations in the bone marrow and brain act as a ticking clock for late-onset leukemia and glioma.
Mitochondrial Cross-talk
Dysregulated IDH1 signaling in the cytoplasm can disrupt the mitochondrial TCA cycle, accelerating bioenergetic aging.
Inflammaging Nexus
The metabolic imbalances caused by low IDH1 activity can trigger innate immune responses in aging tissues.
Longevity Selection
Variants that support robust, non-mutant IDH1 activity are being studied for their role in maintaining metabolic and genomic stability.
Disorders & Diseases
Glioma (Low-Grade)
IDH1 R132H is the definitive marker. It defines a specific clinical subtype of brain tumor with unique growth patterns and prognosis.
Acute Myeloid Leukemia (AML)
IDH1 mutations occur in ~10% of AML cases, driving the "epigenetic block" that prevents blood cells from maturing.
Chondrosarcoma
A bone cancer frequently driven by IDH1 mutations, leading to the accumulation of 2-HG in cartilage cells.
Maffucci Syndrome
A rare condition characterized by multiple benign bone tumors and blood vessel growths, often caused by mosaic IDH1 mutations.
Ollier Disease
Similar to Maffucci, a disorder of cartilage overgrowth driven by somatic IDH1 variants early in development.
The Oncometabolite Paradox
IDH1 taught us that a metabolic chemical can cause cancer. 2-HG doesn't damage DNA directly like radiation; instead, it "clogs" the enzymes that are supposed to keep DNA clean and organized. It is a "metabolic toxin" that causes an epigenetic disease.
Interventions
Supplements
A mandatory cofactor for the TET enzymes that 2-HG inhibits; high-dose Vitamin C is being studied to bypass the IDH1-mutant block.
The precursor to NADP+; ensures the body has the substrate needed for the IDH1 enzyme to produce NADPH.
Supplementation with the "healthy" product of IDH1 is being researched for its potential anti-aging and metabolic benefits.
Support the glutathione system that is stressed when IDH1-mediated NADPH production is compromised.
Lifestyle
Reported to modulate the TCA cycle and potentially influence the background metabolic rate of IDH enzymes.
Supports whole-body mitochondrial health and the metabolic flexibility that IDH1 coordinates.
Minimizing exposure to environmental carcinogens reduces the burden on the DNA repair systems that rely on IDH1 signaling.
Ensures the availability of the amino acids required for the synthesis of glutathione and TCA cycle intermediates.
Medicines
A targeted small molecule that specifically inhibits the mutant IDH1 protein, stopping the production of toxic 2-HG.
A next-generation inhibitor that crosses the blood-brain barrier; highly effective for treating IDH-mutant gliomas.
Used in AML to counteract the DNA hypermethylation caused by mutant IDH1 activity.
Mutant IDH1 creates a "BRCA-ness" state in tumors, making them highly sensitive to drugs that block alternative DNA repair paths.
Lab Tests & Biomarkers
Oncology Gold-Standard
The standard pathology test for brain tumor biopsies to confirm the presence of the oncogenic mutation.
Measures the concentration of the oncometabolite in blood or tumor tissue using mass spectrometry or MRI.
Genetic Screening
Used in leukemia diagnostics to identify specific mutations and guide the use of targeted inhibitors.
Assesses IDH1 alongside TP53 and ATRX to categorize the molecular subtype of a glioma.
Imaging
A non-invasive way to "see" the build-up of 2-HG in a living brain tumor before surgery.
Uses specific tracers to measure the metabolic activity and amino acid uptake of IDH-mutant tumors.
Hormonal Interactions
Cortisol Modulator
Stress hormones can influence the global metabolic rate and the priority of the TCA cycle intermediates.
Insulin Regulator
Drives the uptake of glucose that provides the carbon skeletons for IDH1-mediated synthesis.
Thyroid Hormone Upregulator
Increases the synthesis and activity of many metabolic enzymes, including members of the IDH family.
Estrogen Modulator
Reported to impact cellular redox status and potentially interact with the IDH1 antioxidant network.
Deep Dive
Network Diagrams
IDH1: The Metabolic Switch
The Metabolic Engine: IDH1, α-KG, and NADPH
To understand IDH1, one must view the cell as a chemical factory that produces both fuel and signals. IDH1 is the primary engine located in the cytoplasm of the cell.
The Healthy Products: In a normal, healthy cell, IDH1 takes isocitrate and turns it into two vital products:
- alpha-Ketoglutarate (α-KG): A critical molecular “signal” required for the enzymes that manage our DNA and our response to low oxygen.
- NADPH: The universal cellular “reducing currency” needed to recharge our antioxidants and build healthy fats.
The Redox Master: By producing NADPH, IDH1 is the master regulator of the cell’s “shield” against oxidative stress. It ensures the cell can neutralize free radicals before they can damage proteins and DNA.
The Oncogenic Neo-morph: The Smog Factory
The most significant discovery in brain tumor research was how a mutation in IDH1 can turn a “clean” engine into a toxic smog factory.
The R132H Mutation (rs121913500): This mutation happens at the very heart of the enzyme. It doesn’t just break the protein; it gives it a new, dangerous job (a neo-morphic activity).
- The Oncometabolite: Instead of making α-KG, the mutant enzyme begins to produce a rare chemical called 2-hydroxyglutarate (2-HG).
- The Competition: 2-HG is a “fake” signal. It is shaped like α-KG and it competes for the same spots in the cell’s DNA-managing machinery.
Epigenetic Hijacking: 2-HG and the Glioma Map
The production of 2-HG is the definitive event that drives the development of gliomas (brain tumors) and certain types of leukemia.
The Clogged Demethylases: In a healthy cell, enzymes called TET proteins use α-KG to “wash away” old methyl marks from the DNA, keeping the genetic code clean and readable. In an IDH1-mutant cell, the toxic 2-HG “clogs” these TET proteins.
- Hyper-methylation: The methyl marks accumulate like dirt on a window. Eventually, the entire genetic program of the cell is “blacked out.”
- Immortal Immobility: The cell becomes unable to mature or differentiate. It is locked in a primitive, rapidly dividing state—the hallmark of cancer.
Therapeutic Breakthrough: Because the tumor is “addicted” to this toxic 2-HG smog, scientists have developed drugs (like Vorasidenib) that specifically block the mutant IDH1 engine. By shutting down the smog factory, these drugs can “unclog” the DNA-repair machinery and slow down the growth of the tumor, proving that metabolic correction is a powerful new tool in oncology.
Practical Note: The Metabolic Toxin
2-HG is a molecular "wrench." Think of 2-HG as a wrench thrown into the gears of the cell's repair system. It is physically similar to alpha-ketoglutarate, so it gets stuck in the enzymes that manage your DNA. If you have an IDH1 mutation, the goal of treatment is to stop the "smog factory" from making this wrench.
Vitamin C Synergy. The TET enzymes that 2-HG inhibits *require* Vitamin C to work. High doses of Vitamin C may help "unclog" these enzymes by providing a massive surplus of the healthy co-factor, offering a non-toxic way to support the anti-cancer effort in IDH-mutant patients.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first discovered IDH1 mutations in brain tumors, revolutionizing neuro-oncology.
Pivotal discovery of the "neo-morphic" enzyme activity, establishing 2-HG as the primary driver of IDH-mutant cancers.
Elucidated how the oncometabolite 2-HG clogs the TET enzymes to rewire the cell's entire epigenetic program.
Provided the first high-resolution crystal structure of the mutant enzyme, explaining its shift in substrate preference.
Pivotal Phase 3 trial proving that targeted IDH inhibition significantly delays tumor progression in patients with brain cancer.